[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)


Understand the influence of COVID-19 on the Diabetic Retinopathy Market with our analysts monitoring the situation across the globe.

Global Statistics Representing Diabetic Retinopathy Market Scenario

Diabetic retinopathy affects eyes and damages blood vessels of light-sensitive tissue at the back of the eye. According to the National Eye Institute, in 2014, approximately 7.7 million people suffered from diabetic retinopathy across the globe. Increasing prevalence of diabetic retinopathy across the globe is accelerating demand for diabetic retinopathy. According to the International Diabetes Federation (IDF), in 2015, approximately 415 million people suffered from diabetes globally, with 90% cases of type 2 diabetes representing 8.3% of the adult population. In addition, research & development initiatives, technological advancements, and improved healthcare facilities are expected to propel market growth. Changing lifestyle and increasing consumption of fast food are resulting in the high prevalence of obesity, which in turn is increasing the prevalence of diabetes.

The global diabetic retinopathy market accounted for over USD 6,810 million in 2017 and is expected to grow at a CAGR of 8.7% during the forecast period, 2019–2026.

Intended Audience

  • Pharmaceutical Industry
  • Hospital and Clinics
  • Research and Development (R&D) Companies
  • Potential Investors
  • Research and Development Institutes

Segmentation Insights

The global diabetic retinopathy market can be segmented by type and treatment type.

On the basis of type, the market can be segmented into proliferative diabetic retinopathy and diabetic macular edema (DME). The non-proliferative diabetic retinopathy (NPDR) segment is expected to hold a major market share, owing to high prevalence among patients within the bracket of less than 10 years of diabetic history.

Based on the treatment type, the market can be segmented into anti-VEGF drug, steroid implants, laser surgeries and vitrectomy. The anti-VEGF segment is expected to hold a major market share, owing to the high applicability of these drugs in the treatment of early diagnosis cases to facilitate rapid recovery.

Regional Analysis

Geographically, the global diabetic retinopathy market can be segmented into North America, Europe, Asia-pacific, and LAMEA.

North America is expected to hold a major market share due to the high prevalence of diabetes in the region. Obesity is a leading factor driving the prevalence of diabetes and in turn, growth of the diabetic retinopathy market. According to the Center for Disease Control and Prevention (CDC), in 2014, approximately 100 million among the U.S population had diabetes.

Europe is expected to hold a significant share of the diabetic retinopathy market, owing to the increasing prevalence of diabetes diseases, which in turn can be attributed to increasing environmental pollution and genetic disorders. According to the British Diabetic Association, in 2017, approximately 3.1 million people suffered from diabetes in the U.K. Apart from this, increasing government support to the diabetic patients by launching favorable reimbursement policies is also supporting market growth.

Asia Pacific is pegged to be the fastest growing market, due to the increasing prevalence of genetic diseases such as diabetics, and heart diseases. Additionally, government initiatives increasing awareness regarding diabetes are also expected to support market growth. For instance, government schemes such as Ayushman Bharat-National Health Protection Mission, and Indradhanus for chronic diseases are expected to drive market growth in India.

Latin America is expected to grow at a steady pace despite slow economic growth, backed by a growing healthcare sector.  The Middle East & Africa region holds the least market share due to poor healthcare infrastructure, and limited availability of funds in Africa.

Key Players

Some of the major players in the diabetic retinopathy market include F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer, Inc., Bayer AG, Isis Pharmaceuticals, Inc., Valeant Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc, Abbott Laboratories, Inc. and Allergan Inc.,

Diabetic Retinopathy Market: Segmentation

By Type

  • Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema (DME)

By Treatment Type

  • Anti VEGF Drug
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy

By Regional Covered

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Why Buy This Report?

  • Historical inferences, findings & analysis of the market for the duration of 2016 to 2018
  • Projections and performance forecast analysis for the duration of 2019 to 2026
  • Production and consumption point-of-view (POV) analysis
  • Market driver, restraint and opportunity analysis to define market dynamics, covering industry, regulatory, innovation, technological, and pricing trends

Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports